Voyager Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)

Three Months Ended · Six Months Ended
June 30, · June 30,
2026 · 2025 · 2026 · 2025
Collaboration revenue	$	3,165	$	5,200	$	5,758	$	11,673
Operating expenses:
Research and development		22,041		31,330		46,643		62,856
General and administrative		7,516		10,495		15,777		20,135
Total operating expenses		29,557		41,825		62,420		82,991
Operating loss		(26,392)		(36,625)		(56,662)		(71,318)
Other income, net:
Interest income		1,528		2,831		3,440		6,122
Other income		411		427		846		845
Total other income, net		1,939		3,258		4,286		6,967
Loss before income taxes		(24,453)		(33,367)		(52,376)		(64,351)
Income tax provision		20		15		34		52
Net loss	$	(24,473)	$	(33,382)	$	(52,410)	$	(64,403)
Other comprehensive (loss) income:
Net unrealized (loss) gain on available-for-sale securities		(158)		(22)		(453)		186
Total other comprehensive (loss) income		(158)		(22)		(453)		186
Comprehensive loss	$	(24,631)	$	(33,404)	$	(52,863)	$	(64,217)
Net loss per share, basic and diluted	$	(0.40)	$	(0.57)	$	(0.87)	$	(1.10)
Weighted-average common shares outstanding, basic and diluted		60,547,863		58,666,460		60,025,001		58,508,989

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.